ADDERALL XR 30
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ADDERALL XR 30 (ADDERALL XR 30).
Adderall XR is a central nervous system (CNS) stimulant. It contains a mixture of amphetamine salts (dextroamphetamine and levoamphetamine). Amphetamines are non-catecholamine sympathomimetic amines that promote release of catecholamines (primarily dopamine and norepinephrine) from presynaptic nerve terminals and inhibit their reuptake, leading to increased synaptic concentrations. The exact mechanism of action in attention deficit hyperactivity disorder (ADHD) is not fully understood but is thought to involve activation of dopaminergic and noradrenergic pathways in the prefrontal cortex.
| Metabolism | Amphetamine is metabolized primarily in the liver via cytochrome P450 enzymes, including CYP2D6, and undergoes deamination, oxidation, and conjugation. Minor pathways involve CYP2C19 and CYP3A4. |
| Excretion | Renal: approximately 90% (30–40% unchanged, remainder as metabolites including dehydroamphetamine and hydroxylated metabolites). Fecal: <4%. Biliary: minimal. |
| Half-life | The terminal elimination half-life is 10–13 hours for dextroamphetamine (the more active enantiomer) in adults; for the racemic mixture (dextroamphetamine/amphetamine), the half-life is shorter (6–8 hours) due to differential metabolism. Clinical context: Steady-state achieved within 2–3 days; once-daily dosing is sufficient. |
| Protein binding | Plasma protein binding: approximately 20% (low binding). Binding proteins: albumin and α₁-acid glycoprotein. |
| Volume of Distribution | Vd: 3–4 L/kg (approx. 3.0–4.0 L/kg). Clinical meaning: Indicates extensive extravascular distribution, consistent with high central nervous system penetration. |
| Bioavailability | Oral bioavailability: approximately 95% (for the racemic mixture; unaffected by food, but food may delay peak concentrations). |
| Onset of Action | Oral: 1–2 hours for initial clinical effect (improved attention, reduced impulsivity). Peak effect occurs at approximately 3 hours post-dose. |
| Duration of Action | Duration of clinical effect: 10–12 hours for the extended-release formulation ADDERALL XR, due to the dual-pulse delivery system (immediate-release beads and delayed-release beads). Clinical note: Some patients may experience a shorter duration of benefit; evening rebound effects may occur as drug levels decline. |
| Molecular Weight | 368.2 |
20-60 mg orally once daily in the morning; start at 20 mg once daily, titrate by 10 mg weekly based on tolerability and response.
| Dosage form | CAPSULE, EXTENDED RELEASE |
| Renal impairment | GFR 15-89 mL/min: no adjustment needed; GFR <15 mL/min: avoid use or reduce dose by 50% and monitor; hemodialysis: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use. |
| Pediatric use | For ADHD in children aged 6-12 years: starting dose 10 mg once daily in the morning; may increase by 5-10 mg weekly; maximum 30 mg/day. For adolescents 13-17 years: start 10 mg once daily; titrate to a maximum of 40 mg/day. |
| Geriatric use | Start at the lowest available dose (10 mg once daily) and titrate cautiously due to higher risk of cardiovascular events, insomnia, and decreased renal function; monitor blood pressure and heart rate regularly. |
| 1st trimester | Increased risk of congenital malformations, particularly cardiovascular and oral clefts, with first-trimester exposure. Use only if benefit outweighs risk. |
| 2nd trimester | May increase risk of preterm delivery and low birth weight. Monitor for maternal hypertension and tachycardia. |
| 3rd trimester | Risk of neonatal withdrawal symptoms (e.g., irritability, feeding difficulties) and neonatal toxicity (e.g., tachycardia, hypertension). Use only if clearly needed. |
Clinical note
Comprehensive clinical and safety monograph for ADDERALL XR 30 (ADDERALL XR 30).
| Placental transfer | Amphetamine crosses the placenta; fetal concentrations are similar to maternal levels. |
| Breastfeeding | Amphetamine salts are excreted into breast milk in low concentrations. Irritability, poor feeding, and sleep disturbances have been reported in infants. Consider delaying breastfeeding for 4-6 hours after last dose or avoid use during breastfeeding unless essential. |
■ FDA Black Box Warning
WARNING: ABUSE AND DEPENDENCE. CNS stimulants, including Adderall XR, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.
| Serious Effects |
Hypersensitivity to amphetamine productsConcurrent use or within 14 days of MAO inhibitorsGlaucomaAdvanced arteriosclerosisSymptomatic cardiovascular diseaseModerate to severe hypertensionHyperthyroidismAgitated statesHistory of drug abuse
| Precautions | Serious cardiovascular events: Sudden death, stroke, and myocardial infarction have been reported in patients with structural cardiac abnormalities or other serious heart problems., Blood pressure and heart rate increases: Monitor vitals; use with caution in patients with hypertension or tachycardia., Psychiatric adverse reactions: May exacerbate pre-existing psychosis, mania, or aggression; screen for bipolar disorder., Seizures: May lower seizure threshold; use with caution in patients with seizure disorders., Peripheral vasculopathy, including Raynaud's phenomenon., Serotonin syndrome risk, especially with concomitant serotonergic drugs., Growth suppression: Monitor height and weight in pediatric patients., Long-term suppression of growth has been reported. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Pregnancy Category C. First trimester: Limited human data; animal studies show increased fetal malformations (e.g., cardiac, orofacial) at high doses. Second/third trimester: Risk of premature delivery, low birth weight, neonatal withdrawal (irritability, dysphoria). |
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, weight gain; fetal growth ultrasound and amniotic fluid index; neonatal monitoring for withdrawal symptoms if used near term. |
| Fertility Effects | May impair female fertility in animal studies; effects in humans unclear. Potential for hormonal disruption. |
| Food/Dietary | Avoid high-fat meals within 1 hour before or after administration, as they delay absorption and reduce peak concentration. Avoid acidic foods or drinks (e.g., citrus fruits, vinegar) as they may decrease absorption. Do not consume alcohol because of potential for increased central nervous system side effects and altered release characteristics. |
| Clinical Pearls | Administer once daily in the morning. Avoid late-afternoon or evening dosing to prevent insomnia. Swallow capsule whole; do not chew or crush. Monitor for cardiovascular events (palpitations, hypertension, tachycardia) and psychiatric adverse effects (agitation, psychosis). Use with caution in patients with pre-existing cardiac abnormalities, hyperthyroidism, or glaucoma. Not recommended for patients with a history of drug abuse. Discontinue if new-onset seizures or visual disturbances occur. |
| Patient Advice | Take exactly as prescribed; do not increase the dose or frequency. Do not crush or chew the capsule; swallow it whole with water. Take in the morning to avoid trouble sleeping. · Do not take with high-fat meals as they may delay absorption. Avoid alcohol during treatment. · Report any chest pain, shortness of breath, fainting, or fast/irregular heartbeat to your doctor immediately. · This drug can be habit-forming; keep it in a safe place away from others. Do not share your medication. · Common side effects include decreased appetite, dry mouth, headache, stomach upset, and nervousness. Contact your doctor if these persist or worsen. |